AUS
NZ
UK
CA
USA
IND
Cogstate Ltd, a global leader in neuroscience endpoint solutions, has announced a record $89 million in net sales contracts for the fiscal year ending June 2026, marking a 116% increase from the prior year. The company also reported a significant rise in contracted future revenue, strengthening its financial outlook for FY27.
Key Points
- Cogstate Ltd (ASX:CGS)
- Record $89 million net sales contracts for FY26
- Contracted future revenue reaches $118.5 million for FY27
- FY26 Annual Report scheduled for release on 18 August 2026
Cogstate Posts Record Sales Contracts in FY26
Cogstate Ltd reported a record-breaking $89 million in net sales contracts for the fiscal year ending June 2026, representing a 116% increase compared to $41.3 million in FY25. This remarkable growth highlights the company’s expanding influence in the neuroscience endpoint market, where it collaborates with pharmaceutical and biotechnology firms to deliver essential clinical trial data.
The company’s success in securing substantial sales contracts underscores its competitive advantage in the Central Nervous System (CNS) measurement sector. Cogstate’s technology and services play a crucial role in ensuring clinical trial data is accurate and actionable, driving its growing market presence.
Enhanced Revenue Visibility with $118.5 Million in Future Contracts
Looking forward to FY27, Cogstate reported contracted future revenue totaling $118.5 million, a 32% increase year-over-year. Of this amount, $48.3 million is anticipated to be recognized as revenue in FY27, reflecting a 54% rise from the previous year. This boost in revenue visibility signals a positive outlook for the company’s financial health and strategic initiatives.
The contracted future revenue includes $46.1 million derived from clinical trials, marking a 58% increase from $29.2 million at the end of June 2025. Meanwhile, contracted healthcare revenue remains steady at $2.3 million year-over-year, indicating stable performance in that segment.
Clinical Trials Propel Revenue Expansion
Cogstate’s growth in contracted revenue is primarily driven by its clinical trials division, which has experienced heightened demand for its services. The company enters into agreements with pharmaceutical and biotechnology organizations to provide technology and services that evaluate the cognitive effects of investigational compounds. These contracts form the foundation of Cogstate’s revenue model, with revenue recognized over the contract duration based on predetermined milestones.
The duration of clinical trials varies widely, ranging from several months for phase 1 studies to up to five years for phase 3 trials. This variation in contract length and complexity influences the company’s revenue recognition process and impacts financial results across multiple periods.
FY26 Annual Report Release and Investor Call Scheduled
Cogstate plans to release its audited FY26 Annual Report and Appendix 4E on 18 August 2026. On the same day, the company will host an investor call at 12:00pm AEST, during which management will review FY26 results and outline priorities for FY27. Investors can register for the call through Cogstate’s website.
During the call, management is expected to discuss growth strategies, planned technology investments, and capital allocation plans, offering valuable insights into the company’s future direction and growth prospects.
Cogstate’s Expertise in CNS Measurement Market
Cogstate Ltd specializes in CNS measurement by delivering innovative solutions that improve the precision and usability of clinical trial data. Its applied technology offerings include data quality programs, advanced analytics, and digital cognitive testing, all designed to provide clear signals for confident decision-making in complex neuroscience research.
Beyond clinical trials, Cogstate is active in the healthcare market, offering primary care physicians and consumers brief, accurate, and scientifically validated digital cognitive assessments. These self-administered tests aim to inform patients while saving physician time, further expanding Cogstate’s impact within healthcare.
Insights into Cogstate’s Revenue Model
Cogstate’s revenue model is based on sales contracts with pharmaceutical and biotechnology companies. Contract values vary depending on the scope of services, technology provided, and trial complexity and duration. Growth in total sales contract value contributes to the company’s revenue backlog, which gradually converts into recognized revenue.
Revenue is recognized over the life of each contract, with timing influenced by milestone achievements. This approach offers revenue stability and predictability but also introduces variability based on contract execution timing and milestone completion.
Investor Risks and Considerations
Despite Cogstate’s strong recent performance and improved revenue visibility, investors should consider potential risks. Company results depend on the timing of contract signings and enrollment rates in customer trials, factors beyond Cogstate’s control. Additionally, reliance on the CNS measurement market means shifts in industry dynamics could affect future outcomes.
Investors should also review forward-looking statements in Cogstate’s disclosures, which rely on assumptions subject to change. As with any investment, thorough due diligence and consultation with a financial adviser are recommended.
